PMID- 36313879
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 10
DP  - 2022
TI  - T-cell depleted haploidentical hematopoietic cell transplantation for pediatric 
      malignancy.
PG  - 987220
LID - 10.3389/fped.2022.987220 [doi]
LID - 987220
AB  - Access to allogenic hematopoietic cell transplantation (HCT), a potentially 
      curative treatment for chemotherapy-resistant hematologic malignancies, can be 
      limited if no human leukocyte antigen (HLA) identical related or unrelated donor 
      is available. Alternative donors include Cord Blood as well as HLA-mismatched 
      unrelated or related donors. If the goal is to minimize the number of HLA 
      disparities, partially matched unrelated donors are more likely to share 8 or 9 
      of 10 HLA alleles with the recipient. However, over the last decade, there has 
      been success with haploidentical HCT performed using the stem cells from HLA 
      half-matched related donors. As the majority of patients have at least one 
      eligible and motivated haploidentical donor, recruitment of haploidentical 
      related donors is frequently more rapid than of unrelated donors. This advantage 
      in the accessibility has historically been offset by the increased risks of graft 
      rejection, graft-versus-host disease and delayed immune reconstitution. Various 
      ex vivo T-cell depletion (TCD) methods have been investigated to overcome the 
      immunological barrier and facilitate immune reconstitution after a haploidentical 
      HCT. This review summarizes historical and contemporary clinical trials of 
      haploidentical TCD-HCT, mainly in pediatric malignancy, and describes the 
      evolution of these approaches with a focus on serial improvements in the kinetics 
      of immune reconstitution. Methods of TCD discussed include in vivo as well as ex 
      vivo positive and negative selection. In addition, haploidentical TCD as a 
      platform for post-HCT cellular therapies is discussed. The present review 
      highlights that, as a result of the remarkable progress over half a century, 
      haploidentical TCD-HCT can now be considered as a preferred alternative donor 
      option for children with hematological malignancy in need of allogeneic HCT.
CI  - (c) 2022 Takahashi and Prockop.
FAU - Takahashi, Takuto
AU  - Takahashi T
AD  - Pediatric Stem Cell Transplantation, Boston Children's Hospital/Dana-Farber 
      Cancer Institute, Boston, MA, United States.
AD  - Department of Experimental and Clinical Pharmacology, University of Minnesota 
      College of Pharmacy, Minneapolis, MN, United States.
FAU - Prockop, Susan E
AU  - Prockop SE
AD  - Pediatric Stem Cell Transplantation, Boston Children's Hospital/Dana-Farber 
      Cancer Institute, Boston, MA, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221014
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC9614427
OTO - NOTNLM
OT  - cellular therapy
OT  - children
OT  - cliniMACS
OT  - immune reconsitition
OT  - stem cell transplant
COIS- SEP receives support for the conduct of sponsored trials from Atara 
      Biotherapeutics, Jasper and AlloVir. Has served as a consultant to CellEvolve, 
      Smartimmune and ADMA. Has generated IP related to the use of adoptive cell 
      therapy for EBV and CMV with all rights assigned to Memorial Sloan Kettering 
      Cancer Center.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/10/14
CRDT- 2022/10/31 05:07
PHST- 2022/07/05 00:00 [received]
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/10/31 05:07 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/10/14 00:00 [pmc-release]
AID - 10.3389/fped.2022.987220 [doi]
PST - epublish
SO  - Front Pediatr. 2022 Oct 14;10:987220. doi: 10.3389/fped.2022.987220. eCollection 
      2022.